Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.
about
Towards Development of Small Molecule Lipid II Inhibitors as Novel AntibioticsStructure-activity exploration of a small-molecule Lipid II inhibitorA Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionAryl rhodanines specifically inhibit staphylococcal and enterococcal biofilm formation.Hybrid antibacterials. DNA polymerase-topoisomerase inhibitorsChallenges of antibacterial discoveryDNA polymerase III α subunit from Mycobacterium tuberculosis H37Rv: Homology modeling and molecular docking of its inhibitorCharacterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coliStructure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target.Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds.Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.New quinolone antibiotics: a survey of the literature from 2005 to 2010.Novel heterodimer antibiotics: a review of recent patent literature.Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance.Novel avenues for Clostridium difficile infection drug discovery.Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials.DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Identification of potential drug targets by subtractive genome analysis of Escherichia coli O157:H7: an in silico approach.Bifunctional antimicrobial conjugates and hybrid antimicrobials.MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.DNA Targeting as a Likely Mechanism Underlying the Antibacterial Activity of Synthetic Bis-Indole Antibiotics.Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules.
P2860
Q28552923-BE784DB2-E4A6-4F81-B3D6-D96351757FDBQ28647950-E8215B33-D6F1-424E-A9DC-FE4A84EA4FA5Q30240264-CEB1905A-4AB9-493A-8861-66D228D35698Q30482245-69518657-DCA2-4230-B24D-9B1396B5AF82Q33234000-5DBABCA6-9733-487B-B415-AEDE42601FFDQ33793074-CEA850AB-0C6E-4DBF-86EA-04DD9AC4E03AQ34864729-F3B270CE-43C6-4AA2-813A-DA2B80B7B033Q35046034-3874D770-AAD5-400A-B054-FA9DC9AD1DCDQ35434831-84FCD62B-7E15-4E85-BBCF-E857737B19CBQ35791501-35EBAAFE-077C-402E-AB67-1AE6BAAD678EQ36011938-3104A840-46B3-4709-BE7B-CC15A83D49A9Q37392700-EA257343-8A21-4DB8-BD22-837255AEB114Q37774376-8103B9F5-33D4-4F0D-B6D7-496363166909Q37855823-25745F8D-3E36-4B50-BFFE-5727C7827326Q38028573-F673BB32-A3DB-40A3-86AE-CEF47A719A95Q38083297-5D07A3E5-0F48-4C48-A528-4E2280B125F4Q38137920-F07A06C4-3CBE-4782-8483-75D7268C6BC1Q39078552-2DE5107E-D963-45AD-BCD2-FA1CE7590B2BQ39686067-6A667BD0-8343-4A1B-BFE5-C02D64E3D0EAQ40126498-4885C9D6-9623-48C9-AE4F-95EAED00CA4DQ40203926-DAE9ACB1-5380-43D6-B4A6-6CBD5E2F3261Q42281252-276C37E0-AD1B-43A5-9A1E-A4DBBBD5AFC5Q42364863-909FBFBC-F87F-4C2C-AF6B-04C6AC588BBBQ46478240-7CEA843A-0E10-4B6B-8981-1C2C2E637E06Q55407405-3183FE9B-1EF8-45BA-95DC-CEA121903224
P2860
Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@ast
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@en
type
label
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@ast
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@en
prefLabel
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@ast
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@en
P2093
P2860
P356
P1476
Antibacterial activity and mec ...... uoroquinolone hybrid compound.
@en
P2093
Chengxin Zhi
Donna J Skow
George E Wright
Kimberly A Foster
Lauren M Kustigian
Marjorie H Barnes
Michelle M Butler
Neal C Brown
Patrick T Lyden
Terry L Bowlin
P2860
P304
P356
10.1128/AAC.01311-05
P407
P577
2006-10-30T00:00:00Z